Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide and Radiotherapy in PSMA-detected Advanced Prostate Cancer
NCT04319783Phase 2Active, not recruiting
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Jun 2021
- Primary completion
- Jun 2026
- Countries
- 2
01
Overview
A Phase 2 trial of darolutamide in prostate cancer (PCa), sponsored by Trans-Tasman Radiation Oncology Group. Started Jun 2021; status: active, not recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04319783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04319783.